What I have: reflux · semaglutide · STEP 3.
I can parse the result. I am less sure what it licenses me to conclude.
I have deliberately not looked at anyone else’s interpretation yet.
What does this actually establish, and what does it not?
Take it from the STEP 3 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.
The relevant physiology is that gastric emptying slows substantially and then partially normalises with continued exposure at a stable dose.
Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.
More usefully, reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.
Dietary fat slowing gastric emptying is basic gastrointestinal physiology and independent of any drug effect.
Symptoms appearing late at a stable dose deserve a differential diagnosis rather than an assumption.
Everything except constipation attenuates. Plan differently for that one.
edited 25 Feb 2025 by v_ramaswamy — added the placebo-arm figures
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsIn practice, this is the group of effects that drives almost all discontinuation in the trial programmes.
Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.
The underlying point is that anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.
Research-use compounds are not approved for human use.
Smaller meals, less fat, fluids between rather than with. In that order.
Answer first: the gastrointestinal effects in this class share one mechanism — slowed gastric emptying plus central signalling — and present as nausea, fullness, reflux, constipation or diarrhoea depending on the person.
Symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Slow the titration first. It is the intervention with the best evidence and the lowest cost.
The honest answer is that the first eight weeks are the hard part and that most people who get through them stop having the conversation.
The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.
The caveat is that severe persistent symptoms, particularly with dehydration or severe pain, are clinical and not a matter of waiting them out.
Most people who report these effects continue. The discontinuation rate is low.
Worth being precise here: diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.
Nothing here is medical advice.
New symptoms at a stable dose after months need a different explanation.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.